| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. | Director | Common Stock | 89.6K | $1.07M | $11.98 | Jun 21, 2024 | Direct |
| Monte Rosa Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 22.1K | Jun 12, 2024 | Direct | ||
| Trillium Therapeutics Inc. | President and CEO, Director | Stock Option (Right to Buy) | 0 | Nov 17, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | Jun 21, 2024 | 1 | $0 | 4 | Jun 21, 2024 | Director |
| GLUE | Monte Rosa Therapeutics, Inc. | Jun 12, 2024 | 1 | $0 | 4 | Jun 13, 2024 | Director |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Sep 11, 2023 | 1 | -$125K | 4 | Sep 13, 2023 | Director |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Jun 16, 2023 | 1 | $0 | 4 | Jun 16, 2023 | Director |
| GLUE | Monte Rosa Therapeutics, Inc. | Jun 14, 2023 | 1 | $0 | 4 | Jun 15, 2023 | Director |
| GLUE | Monte Rosa Therapeutics, Inc. | Mar 30, 2023 | 1 | $0 | 4 | Mar 31, 2023 | Director |
| GLUE | Monte Rosa Therapeutics, Inc. | Mar 23, 2023 | 0 | $0 | 3 | Mar 24, 2023 | Director |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Sep 9, 2022 | 1 | $0 | 4 | Sep 12, 2022 | Director |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Sep 9, 2022 | 0 | $0 | 3 | Sep 12, 2022 | Director |
| TRIL | Trillium Therapeutics Inc. | Nov 17, 2021 | 3 | $0 | 4 | Nov 19, 2021 | President and CEO, Director |
| TRIL | Trillium Therapeutics Inc. | May 11, 2021 | 8 | -$1.15M | 4 | May 13, 2021 | President and CEO, Director |